Silence Therapeutics
 | |
| Type | Public (LSE: SLN) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1994 |
| Headquarters | Hammersmith, London |
Number of employees | 50 |
| Website | www.silence-therapeutics.com |
Silence Therapeutics (AIM:SLN[1]) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters in Hammersmith, London.
Profile[]
The targeting, delivery and ongoing structural modification of sequences are the three platforms for Silence Therapeutics's RNAi therapeutic development. These three platforms are:
- proprietary siRNA sequences complied using bioinformatics algorithms and scientific research conjugated with GalNac Technology
- development of siRNA structural features
History[]
In 2005, the company acquired Atugen AG based in Germany, changing the company name to Silence Therapeutics. In 2010, Silence Therapeutics merged with Intradigm Corporation, a privately held biotechnology company in the United States that developed systematic RNA interference.[2]
Partnerships[]
Silence Therapeutics has multiple partnerships with other pharmaceutical companies, such as Mallinckrodt Pharmaceuticals, Takeda and Quark Pharmaceuticals.
References[]
- ^ "Google Finance Stock Exchange listing for Silence Therapeutics". Retrieved 2011-09-16.
- ^ "Stockopedia - Silence Therapeutics Company History". Stockopedia. Retrieved 2011-09-16.
External links[]
Authority control  |
|
|---|
- Pharmaceutical companies of England
- Medical and health organisations based in England
- Companies based in the London Borough of Hammersmith and Fulham
- 1994 establishments in England
- Pharmaceutical companies established in 1994